Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2017

01-11-2017 | Research Article

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

Authors: V. López-López, P. A. Cascales-Campos, E. Gil, J. Arevalo, A. Gonzalez, J. Gil, F. C. Muñoz-Casares, J. T. Melero, P. Barrios, R. Morales, I. Ramos, G. Ortega, B. Camps, L. González-Bayón, P. Bretcha-Boix, J. Farré-Alegre, S. González-Moreno, P. Parrilla

Published in: Clinical and Translational Oncology | Issue 11/2017

Login to get access

Abstract

Background

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei and appendix tumours are widespread in the world. It is unclear what should be the attitude in elderly patients.

Methods

This retrospective multicenter study collected the database from ten Spanish centers from Spanish Group of Peritoneal Cancer Surgery. The study period was between November 2002 and March 2014. Seventeen patients with age greater than or equal to 75 years with peritoneal carcinomatosis from pseudomyxoma peritonei and appendix tumours met the selection criteria for the study. Outcomes in terms of morbidity and mortality such as disease-free and overall survival were analyzed.

Results

Median PCI was 16 (range 6–39). Ten postoperative adverse events were detected in nine patients (44.4%). 28% were grade I–II and 17% were grade III–IV. Disease-free survival at 1 and 3 years was 67 and 44%, respectively. Overall survival at 1 and 3 years was 100 and 88%, respectively. Only cytoreduction was related to worst disease free survival after univariate (p = 0.007) and multivariate (OR 11.639, 95% CI 1.24–109.74, p = 0.03) analyses. Cytoreduction was related to the worst overall survival after univariate analysis (p = 0.046).

Conclusion

Cytoreductive surgery and HIPEC for pseudomyxoma peritonei and appendix tumours in elderly patients it is a procedure with feasible postoperative morbi-mortality and survival outcomes.

Trial registration

researchregistry1587 (retrospectively registered).
Literature
1.
2.
Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.CrossRefPubMed
3.
Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomixoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.CrossRefPubMedPubMedCentral
4.
Elias D, Laurent S, Antoun S, et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy [in French]. Gastroenterol Clin Biol. 2003;27:407–12.PubMed
5.
Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393–8.CrossRefPubMed
6.
Güner Z, Schmidt U, Dahlke MH, Schlitt HJ, Klempnauer J, Piso P. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis. 2005;20:155–60.CrossRefPubMed
7.
Bradley RF, Stewart JH IV, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–9.CrossRefPubMed
8.
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed
9.
Barrios P, Losa F, Gonzalez-Moreno S, et al. Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei). Clin Transl Oncol. 2016;18:437–48.CrossRefPubMed
10.
Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–77.CrossRefPubMed
11.
Fong Y, Blumbart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995;222:426–34.CrossRefPubMedPubMedCentral
12.
Saltzstein SL, Behling CA. 5–10 year survival in cancer patients aged 90 and older: a study of 37318 patients from SEER. J Surg Oncol. 2002;81:113–6.CrossRefPubMed
13.
Moran BJ. Establishment of a peritoneal malignancy treatment centre in the United Kingdom. Eur J Surg Oncol. 2006;32:614–8.CrossRefPubMed
14.
Königsrainer I, Beckert S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we? World J Gastroenterol. 2012;18:5317–20.CrossRefPubMedPubMedCentral
15.
Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg. 2012;255:348–56.CrossRefPubMed
16.
Baratti D, Kusamura S, Laterza B, et al. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol. 2010;2:36–43.CrossRefPubMedPubMedCentral
17.
Macrì A, Arcoraci V, Belgrano V, et al. Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: preliminary analysis of a multicentre study. Anticancer Res. 2014;34:5689–93.PubMed
18.
Tabrizian P, Jibara G, Shrager B, et al. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol. 2013;22:184–9.CrossRefPubMed
19.
Macrì A, Saladino E, Trimarchi G, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients. In Vivo. 2011;25:687–90.PubMed
20.
Spiliotis JD, Halkia E, Boumis VA, et al. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014;98:74–5.
21.
Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20:3497–503.CrossRefPubMed
22.
Cascales-Campos P, Gil J, Gil E, et al. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients. Eur J Obstet Gynecol Reprod Biol. 2014;179:88–93.CrossRefPubMed
23.
Cascales-Campos PA, López-López V, Muñoz-Casares FC, et al. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: spanish group of peritoneal cancer surgery (GECOP) multicenter study. Surg Oncol. 2016;25:111–6.CrossRefPubMed
24.
Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.CrossRefPubMed
25.
Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54:293.CrossRefPubMed
26.
McQuellon R, Duckworth KE. Health-related quality of life and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Curr Probl Cancer. 2009;33:203–18.CrossRefPubMed
27.
Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol. 2010;36:1156–61.CrossRefPubMed
Metadata
Title
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
Authors
V. López-López
P. A. Cascales-Campos
E. Gil
J. Arevalo
A. Gonzalez
J. Gil
F. C. Muñoz-Casares
J. T. Melero
P. Barrios
R. Morales
I. Ramos
G. Ortega
B. Camps
L. González-Bayón
P. Bretcha-Boix
J. Farré-Alegre
S. González-Moreno
P. Parrilla
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1728-9

Other articles of this Issue 11/2017

Clinical and Translational Oncology 11/2017 Go to the issue

Review article

Surgery for pancreatic ductal adenocarcinoma

Research Article

Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells

Brief Research Article

Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60)

Research Article

A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients

Research Article

A logistic regression model predicting high axillary tumour burden in early breast cancer patients

Brief Research Article

Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits